92 related articles for article (PubMed ID: 26572413)
21. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
22. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
23. Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction.
Al-Sadoon MK; Rabah DM; Badr G
Cell Immunol; 2013; 284(1-2):129-38. PubMed ID: 23973876
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel-loaded trimethyl chitosan-based polymeric nanoparticle for the effective treatment of gastroenteric tumors.
Song RF; Li XJ; Cheng XL; Fu AR; Wang YH; Feng YJ; Xiong Y
Oncol Rep; 2014 Oct; 32(4):1481-8. PubMed ID: 25051142
[TBL] [Abstract][Full Text] [Related]
25. Development of chitosan/heparin nanoparticle-encapsulated cytolethal distending toxin for gastric cancer therapy.
Lai CK; Lu YL; Hsieh JT; Tsai SC; Feng CL; Tsai YS; Tsai PC; Su HL; Lin YH; Lai CH
Nanomedicine (Lond); 2014 May; 9(6):803-17. PubMed ID: 24024568
[TBL] [Abstract][Full Text] [Related]
26. Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles.
Chuah LH; Roberts CJ; Billa N; Abdullah S; Rosli R
Colloids Surf B Biointerfaces; 2014 Apr; 116():228-36. PubMed ID: 24486834
[TBL] [Abstract][Full Text] [Related]
27. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
Zhao ZB; Long J; Zhao YY; Yang JB; Jiang W; Liu QZ; Yan K; Li L; Wang YC; Lian ZX
Biomater Sci; 2018 Mar; 6(4):893-900. PubMed ID: 29512660
[TBL] [Abstract][Full Text] [Related]
28. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
Sui J; Cui Y; Cai H; Bian S; Xu Z; Zhou L; Sun Y; Liang J; Fan Y; Zhang X
Nanoscale; 2017 Feb; 9(8):2755-2767. PubMed ID: 28155940
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.
Gillani TB; Rawling T; Murray M
Chem Res Toxicol; 2015 Jan; 28(1):92-102. PubMed ID: 25489883
[TBL] [Abstract][Full Text] [Related]
30. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
32. ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells.
Park GB; Choi Y; Kim YS; Lee HK; Kim D; Hur DY
Int J Oncol; 2014 Mar; 44(3):977-85. PubMed ID: 24402682
[TBL] [Abstract][Full Text] [Related]
33. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
34. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
[TBL] [Abstract][Full Text] [Related]
35. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Ishijima N; Kanki K; Shimizu H; Shiota G
Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
[TBL] [Abstract][Full Text] [Related]
36. Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Liu J; Boonkaew B; Arora J; Mandava SH; Maddox MM; Chava S; Callaghan C; He J; Dash S; John VT; Lee BR
J Pharm Sci; 2015 Mar; 104(3):1187-96. PubMed ID: 25573425
[TBL] [Abstract][Full Text] [Related]
37. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
38. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
[TBL] [Abstract][Full Text] [Related]
39. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
